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Summary
Guidelines on prevention of mother-to-child transmission
(PMTCT) of human immunodeficiency virus (HIV) are
inconsistently implemented in low-income countries.
Strategies are needed to improve the uptake of these
guidelines to prevent avoidable new HIV infections of in-
fants. In 2010 the World Health Organisation presented
its new PMTCT guidelines, offering two options for short
courses of antiretroviral prophylaxis: Option A and Option
B. Option A consists of antenatal prophylaxis with
zidovudine followed by intrapartum and postpartum pro-
phylaxis with single-dose nevirapine and zidovudine plus
lamivudine. Option B recommends triple antiretroviral pro-
phylaxis until after finishing breastfeeding. Tanzania has
adopted Option A, and it is currently implementing it.
A new option termed Option B+ has emerged recently,
which recommends providing lifelong antiretroviral treat-
ment to all HIV-positive pregnant women.
In this article, we discuss the likely impact of this last
PMTCT strategy in rural Africa with an example of an ob-
servational cross-sectional analysis in a rural referral hos-
pital in Tanzania aiming to assess the uptake of PMTCT
recommendations. Gaps were identified at all steps of the
PMTCT pathway.
Effective uptake of PMTCT guidelines has been shown
to be extremely challenging in this setting. The continu-
ously changing recommendations on PMTCT stress the
need for a much simpler and effective approach. We argue
in favour of implementing Option B+ in Tanzania. Finan-
cial challenges need to be faced, but Option B+ would help
to overcome many barriers that prevent guidelines to be
implemented in order to increase coverage and ultimately
achieve the goal of ‘virtual elimination’ of mother-to-child
transmission in sub-Saharan Africa.
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Different options for preventing
mother-to-child transmission of HIV
More than two million children under the age of 15 are in-
fected with human immunodeficiency virus (HIV) world-
wide, most of them in sub-Saharan Africa [1]. Mother-to-
child transmission of HIV accounts for over 90% of these
cases [1], the risk of transmission ranging from 25% to
48% in resource-limited settings [2].
Prevention of mother-to-child transmission (PMTCT) was
shown to be effective in well-resourced settings through the
administration of antiretroviral prophylaxis to the mother
during pregnancy, labour and delivery and to the infant for
the first six weeks of life [3]. Further evidence demon-
strated that combined antiretroviral therapy (cART) given
to the mother together with elective Caesarean section and
avoidance of breastfeeding reduced mother-to-child trans-
mission to less than 1% [4]. Consequently, guidelines were
developed for high- and in low-income countries [5, 6].
The World Health Organisation (WHO) issued the first re-
commendations on PMTCT in resource-limited settings in
2000. These recommendations were revised in 2004 with
the adoption of simplified and standardised regimens. In
2006 and later in 2010 [5], the guidelines were updated to
incorporate new evidence and to be aligned with the global
commitment to universal access.
Guidelines for resource-limited settings are difficult to im-
plement, partly because of the fragility of health systems
in these countries. Lack of infrastructure and constraints
on human and financial resources contribute to a poor up-
take of evidence-based interventions and, ultimately, to the
impairment of clinical practice in these settings. Dissemin-
ation of changes in the guidelines is suboptimal and often
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takes time to take root among health workers and to change
practices in rural sub-Saharan Africa [7]. According to the
WHO, only 53% of pregnant women worldwide received
any antiretroviral for PMTCT in 2009 [8], with substan-
tial differences across countries in sub-Saharan Africa (i.e.
1% in the Democratic Republic of the Congo vs 52% in
Mozambique) [9]. Importantly, having effective antiretro-
viral regimens and wide coverage is insufficient; effective
delivery programmes are equally important [10, 11]. Sim-
plification of the existing programmes is urgently needed
in order to bridge the gaps observed with current recom-
mendations.
In 2010 the WHO presented its new guidelines on PMTCT,
recommending two PMTCT options: Option A and Option
B. These two options include both treatment and prophy-
laxis components. In both options CD4 cell count is ne-
cessary to decide the eligibility of HIV-infected pregnant
women for lifelong cART. For all women who have CD4
cell counts ≤350 cell/mm3 initiation of lifelong cART is
recommended. For those women not eligible for lifelong
cART, Option A recommends antenatal prophylaxis with
zidovudine followed by intrapartum and postpartum pro-
phylaxis with single-dose nevirapine and zidovudine plus
lamivudine; Option B recommends triple antiretroviral pro-
phylaxis until after finishing breastfeeding. Recently a new
option has emerged, termed Option B+ [12]. This option
is a single, universal regimen both to treat HIV-infected
pregnant women and to prevent mother-to-child transmis-
sion. In Option B+ all HIV-positive pregnant women are
provided with lifelong cART, regardless of the CD4 cell
count. Option A might be difficult to implement because
of the different drugs administered during antenatal, intra-
partum and postpartum care. Options B and B+, although
simplifying drug prescription, have a short-term drug cost
greater than Option A. However, when taking into account
maternal and infant life expectancy and lifetime healthcare
costs, Option B is more effective and less expensive than
Option A. Option B+ offers clinical benefits and economic
value comparable to other widely used HIV interventions
[13]. The three options are summarised in table 1.
Several countries in sub-Saharan Africa are currently con-
sidering modifying their PMTCT guidelines. Such a de-
cision should be made on the basis of their implementation
experience and a previous assessment of how they can
better integrate, simplify and optimise the PMTCT pro-
gramme in the existing HIV/AIDS care and treatment plat-
form.
The Tanzanian national guidelines on PMTCT were deve-
loped in 2004 and revised in 2007 [14]. New guidelines re-
commending WHO option A were developed in June 2012
and plans are being devised to implement them nationwide
[15].
A cross-sectional survey in a referral
hospital in Tanzania assessing the
uptake of the current PMTCT
recommendations: an example of
problems encountered in rural sub-
Saharan Africa
In this review we illustrate the problems of PMTCT with
findings of a recently performed survey conducted in
March 2012 in a referral hospital in Tanzania. Data on
PMTCT services delivered between January 2010 and
December 2011 at St Francis referral hospital in Ifakara,
Figure 1
Theoretical care pathway for prevention of mother-to-child
transmission (PMTCT) of human immunodeficiency virus (HIV) at
St Francis Referral Hospital (SFRH).
RCHC = Reproductive and Child Health Clinic; CDCI = Chronic
Disease Clinic of Ifakara; ART = antiretroviral therapy; ARV =
antiretroviral.
Table 1: Options for preventing mother-to-child transmission of human immunodeficiency virus.
Woman receives
Treatment
(CD4 counts ≤350 cells/mm3)
Prophylaxis
(CD4 counts >350 cells/mm3)
Infant receives
Option A Triple ARVs starting as soon as diagnosed and
continued for life
Antepartum: AZT starting as early as 14 weeks
gestation
Intrapartum: at onset of labour, sdNVP and first
dose of AZT/3TC
Postpartum: daily AZT/3TC until 7 days
postpartum
Mother received prophylaxis: daily NVP from birth
until 1 week after cessation of all breastfeeding; if
not breastfeeding until age 4‒6 weeks
Mother is on treatment: daily NVP until age 4–6
weeks
Option B Triple ARVs starting as soon as diagnosed and
continued for life
Triple ARVs starting as early as 14 weeks
gestation and through childbirth if not
breastfeeding, or until 1 week after cessation of
all if breastfeeding
Irrespective of mode of infant feeding: daily NVP
or AZT from birth until age 4–6 weeks
Same for treatment and prophylaxisOption B+
Regardless of CD4 count, triple ARVs starting as soon as diagnosed and continued for life
Irrespective of mode of infant feeding: daily NVP
or AZT from birth until age 4–6 weeks
Triple ARVs means the use of one of the recommended three-drug fully suppressive treatment options.
ARVs = antiretrovirals; AZT = zidovudine; sdNVP = single-dose nevirapine; 3TC = lamivudine; NVP = nevirapine.
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Kilombero district, Morogoro region, Southern Tanzania,
were collected. Table 2 summarises the antiretroviral regi-
mens recommended by the Tanzanian national guidelines
on PMTCT before, during and after delivery. In this article,
we will use this as a case-study to discuss the limitations of
the implementation of guidelines, to identify the gaps to be
bridged, and to envisage potential solutions, including the
adoption of newer PMTCT strategies.
Setting at a rural referral hospital
St Francis referral hospital has 370 beds and is the most
important healthcare facility in the Kilombero district.
PMTCT services are provided by several departments in
this hospital, including the Reproductive and Child Health
Clinic; the Chronic Diseases Clinic of Ifakara; the Obstet-
rics department; and the Neonatology unit.
The Reproductive and Child Health Clinic provides
antenatal care to all pregnant women, as well as vaccin-
ations and outpatient care for children under five years
old. Care and treatment for all HIV-positive patients is
provided at St Francis referral hospital in accordance with
the National AIDS Control Programme through the Chron-
ic Diseases Clinic of Ifakara. The Chronic Diseases Clinic
of Ifakara works in cooperation with the Ifakara Health
Institute, the Swiss Tropical and Public Health Institute
and the Departments of Infectious Diseases and Hospital
Epidemiology of the University Hospitals of Basel and
Bern, Switzerland. All patients attending the Chronic
Diseases Clinic of Ifakara since late 2004 are asked for in-
formed consent to be enrolled at the Kilombero and Ulanga
Antiretroviral Cohort (KIULARCO) [16]. This cohort
comprises almost 6000 patients and is the largest peripheral
HIV cohort in Tanzania.
The Obstetrics department attends approximately 5000 de-
liveries per year and works closely with the Neonatology
unit.
Figure 2
Main gaps identified in the care pathway for prevention of mother-
to-child transmission (PMTCT) of human immunodeficiency virus
(HIV) at St Francis Referral Hospital (SFRH).
The gaps are coloured in brown. RCHC = Reproductive and Child
Health Clinic; CDCI = Chronic Disease Clinic of Ifakara; ART =
antiretroviral therapy; ARV = antiretroviral.
PMTCT Circuit at St Francis referral hospital and
gaps identified
Figure 1 shows the theoretical PMTCT pathway at St Fran-
cis referral hospital. The departments involved in this pro-
cess are the following: Reproductive and Child Health
Clinic, Chronic Diseases Clinic of Ifakara, Obstetrics, and
Neonatology. The following key steps of the PMTCT path-
way were identified: (1.) HIV counselling and testing; (2.)
CD4 count measurement and eligibility for cART; (3.)
antenatal antiretroviral prophylaxis; (4.) intrapartum and
postpartum prophylaxis; (5.) postnatal prophylaxis for the
infant; (6.) follow-up of HIV-positive mothers; and (7.)
follow-up of HIV-exposed infants.
According to the WHO and Tanzanian national guidelines,
all pregnant women attending the Reproductive and Child
Health Clinic for antenatal care have to be offered HIV
counselling and testing. Between January 2010 and
December 2011, 4027 pregnant women attended the Re-
productive and Child Health Clinic. Forty-four (1%) were
already known to be HIV infected. The remainder were
offered HIV testing, with a rate of acceptance of 90.4%
(3606/3983). Two hundred and seven of these 3606 women
tested positive. Thus, the HIV prevalence among pregnant
women attending antenatal services at St Francis referral
hospital during the study period was 6.9% (251/3647). Cur-
rent Tanzanian guidelines recommend HIV seronegative
women to be retested after three months in order to avoid
false negative diagnoses during the ‘window period’ after
acute infection, but there was no information concerning
the proportion of seronegative women who were retested.
Information could only be extracted from randomly selec-
ted individual pregnancy cards, and none of the seronegat-
ive women assessed had a second test registered.
Those women who are newly diagnosed with HIV infec-
tion at St Francis referral hospital should be referred to the
Chronic Diseases Clinic of Ifakara. However, only 25.6%
(53/207) of newly diagnosed women visited the clinic dur-
ing 2010–2011 and were assessed for cART eligibility.
Seventy-four percent (154/207) of HIV-infected women
were not registered at the Chronic Diseases Clinic and
thus cART eligibility criteria were not assessed. Conse-
quently, all HIV-positive pregnant women with unknown
CD4 count were prescribed antenatal antiretroviral prophy-
laxis in the Reproductive and Child Health Clinic, regard-
less of their eligibility for initiation of cART. According to
the labour ward PMTCT log book, the antenatal prophy-
laxis prescribed to all HIV-positive women was monother-
apy with nevirapine, which was not a recommended option
(table 2). This is inconsistent with the information collec-
ted at the Reproductive and Child Health Clinic regarding
antenatal prophylaxis prescribed during the same period,
which was recorded as zidovudine.
All HIV-infected pregnant women are advised to deliver at
St Francis referral hospital to ensure optimal intrapartum
and postpartum antiretroviral prophylaxis for the mother,
and postnatal prophylaxis for the infant. Between 20/03/
2011 and 03/05/2011, 570 women delivered at the hospital.
Almost 5% (28/570) and 80% (456/570) were known to
be HIV-positive and HIV-negative, respectively. The HIV
serostatus was unknown for 14.4% (82/570) of women. Of
those, 2.4% (2/82) were tested during labour, with one test-
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ing HIV-positive. In total, 5.9% (29/486) of all women with
a known HIV serostatus giving birth at St Francis referral
hospital during that period tested positive.
Concerning intrapartum prophylaxis, there was conflicting
information in the register books and the interviews. The
nurses interviewed did not appear to be aware of the latest
recommendations on intrapartum prophylaxis, which in-
clude three drugs to be given at different intervals (table 2).
In contrast, 86% (25/29) of the HIV-positive women were
recorded as having correct prophylaxis with three drugs,
and no information was registered for the remaining four
women.
Regarding postpartum prophylaxis, no information was re-
corded for any women. The interviews with staff members
of the labour and the obstetric wards suggest a lack of clar-
ity with regards to the service responsible for its adminis-
tration.
As postnatal prophylaxis, 83% (24/29) of the babies born
from HIV-seropositive women were given single-dose
nevirapine, one (3.4%) received single-dose nevirapine
plus zidovudine for one week and no data was collected
for the remaining four babies. This represents another im-
portant gap in this pathway, since the postnatal prophylaxis
recommended in the guidelines includes both single-dose
nevirapine plus zidovudine, very rarely administered at St
Francis referral hospital during the period assessed.
After delivery, mother and child should be referred to the
Chronic Diseases Clinic of Ifakara for follow-up. During
2010–2011 only one woman with an infant younger than
two months was registered at the Chronic Diseases Clinic.
There is no information with regards to the number of the
HIV-exposed infants attending the clinic during the same
period. There is neither active case-finding nor a standard-
ised follow-up for HIV-exposed infants in place. Conse-
quently, the infant is visited together with the mother and
information related to the exposed noninfected child is not
collected in any database.
Figure 2 illustrates the gaps identified in the PMTCT al-
gorithm. For every gap identified at different steps of the
PMTCT pathway, the possible causes were assessed and
potential solutions were suggested. Table 3 summarises the
most likely causes and the proposed solutions to close the
specific gaps.
Proposals to increase the uptake of
current and forthcoming PMTCT
guidelines: time for change
The uptake of the guidelines in sub-Saharan Africa is
known to be poor. The aim of this case presentation was
to illustrate the quality of PMTCT provision at a rural Tan-
zanian referral hospital by providing a snapshot of the real-
ity in the field, and to identify existing gaps and potential
ways to bridge them at an operational level. Our findings
should help to develop new potential strategies to be tested
in a prospective fashion with the aim of improving the up-
take of PMTCT guidelines in rural Tanzania and other sim-
ilar settings in sub-Saharan Africa. Moreover, simpler and
more effective approaches need to be considered.
In St Francis referral hospital, all the services and most re-
sources needed for a proper functioning of the Tanzanian
PMTCT programme were in place. However, several gaps
were observed that prevented the current Tanzanian recom-
mendations to be implemented optimally. This is worri-
some, since it may ultimately result in an increasing rate of
HIV infection among infants.
The most important gaps identified in the PMTCT care
pathway were: (a) no retesting of seronegative pregnant
women in late pregnancy; (b) suboptimal follow-up of
HIV-infected pregnant women, including irregular assess-
ment of cART eligibility; (c) inconsistencies in the pre-
scription of antiretroviral prophylaxes; and (d) lack of a
standardised follow-up of HIV-exposed infants.
As mentioned, the Tanzanian Government has adopted Op-
tion A for the new PMTCT Guidelines. Lower short-term
costs might justify the adoption of this strategy in Tanzania.
However, drug prices have been reduced since 2010, when
the WHO recommendations were published, and they are
Table 2: Recommended combination antiretroviral prophylaxis regimens to prevent mother-to-child transmission of HIV according to the 2007 Tanzanian national
guidelines for the Prevention of Mother-To-Child Transmission of HIV.
Regimen Antenatal Intrapartum Postpartum Postnatal
Recommended AZT 300 mg twice daily starting
at 28 WG or as soon as possible
thereafter
AZT 300 mg at onset of labour
and every 3 hours until delivery
sdNVP 200 mg at onset of
labour
3TC 150 mg at onset of labour
and every 12 hours until delivery
AZT 300 mg twice daily for
7 days
3TC 150 mg twice daily for
7 days
sdNVP 2 mg/kg immediately
after birth
AZT 4 mg/kg twice a day for
7 days
Recommended if mother
presents during labour
AZT at 300 mg at onset of
labour and every 3 hours until
delivery
sdNVP 200 mg at onset of
labour
3TC 150 mg at onset of labour
and every 12 hours until delivery
AZT 300 mg twice daily for
7 days
3TC 150 mg twice daily for
7 days
sdNVP 2 mg/kg immediately
after birth
AZT 4 mg/kg twice daily for
28 days
Recommended if mother tests
HIV positive immediately after
delivery
Refer to Care and Treatment
Clinic, do not give any
antiretroviral
sdNVP 2 mg/kg immediately
after birth
AZT 4 mg/kg twice daily for
28 days
Recommended if mother was on
ART before pregnancy
Continue ART prescribed before pregnancy. In the first trimester replace EFV with NVP AZT 4 mg/kg twice a day for
7 days
AZT = zidovudine; WG = weeks of gestation; sdNVP = single-dose nevirapine; 3TC = lamivudine; ART = antiretroviral therapy; EFV = efavirenz; NVP = nevirapine. Source:
Tanzanian national guidelines for the Prevention of Mother-To-Child Transmission of HIV. The United Republic of Tanzania, Ministry of Health and Social Welfare, 2007 [14]
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expected to further decrease, narrowing the cost difference
between Options A and B. There are concerns about the
lack of simplification when switching from the former re-
commendations to Option A. Even if the higher CD4 count
threshold for cART eligibility, the earlier initiation of
antenatal prophylaxis and the longer postnatal prophylaxis
for breastfeeding infants are definitely welcome modific-
ations, the complexity of the regimen remains high and
might prevent correct implementation in the real world, as
shown in the case presented. Simpler strategies are needed
to increase the coverage and the efficacy of these pro-
grammes. Better infrastructure and human resources must
accompany these new strategies to avoid logistic problems
such as drug stock-outs [17] and overburdened health staff.
In 2011, Malawi adopted Option B+, for its ease of imple-
mentation and potential prevention benefit [18]. Likewise,
other countries, such as Uganda and Swaziland, are also
considering moving to Option B+. Using the case presented
as a starting point, we are now going to discuss every gap
observed and envisage what would be the situation if Op-
tion B+ was the adopted PMTCT recommendation in Tan-
zania.
HIV testing was done once and not repeated during the
third trimester among those women who were initially ser-
onegative. In a South African study [19], 3% of initially
seronegative pregnant women were found to be HIV-infec-
ted in late pregnancy, showing the relevance of retesting
during the third trimester. Acute HIV infection during preg-
nancy is associated with high rates of vertical transmission
owing to the extremely high HIV ribonucleic acid (RNA)
levels during this phase of the infection, which is associ-
ated with higher probabilities of vertical transmission [20].
Option A, B or B+ would not bridge this gap, since the
awareness of the importance of retesting has to be spread
through education.
Regarding the assessment of the cART eligibility, the cur-
rent Tanzanian guidelines during the time the analysis was
performed recommended offering cART to all pregnant
women with CD4 counts ≤200 cells/mm3 or ≤350 cells/
mm3 in case of WHO stage 3 or 4 disease. However, our
analysis shows that after being found to be HIV-positive,
most pregnant women were not assessed for cART eligib-
ility. Instead, most were offered antiretroviral prophylax-
is regardless of CD4 cell count. We have to take into ac-
count the possibility that some women attended a clinic
Table 3: Prevention of mother-to-child transmission (PMTCT) care pathway: observed gaps, possible causes, and potential solutions.
Step involved Observed gap Possible causes Potential solutions
HIV testing at RCHC Not all seronegative pregnant women are
retested 3 months after the first HIV-negative
serology.
Unawareness of the ‘window period’ after the
primary HIV infection.
CME. Refresher seminars for all the staff
involved in antenatal care.
SOP.
CDCI After being diagnosed HIV-positive, most
pregnant women do not attend the CDCI, so
CD4 count is not measured and ART eligibility is
not assessed.
Pregnant women do not seem to feel
comfortable attending the CDCI. According to
the nurses’ interviews, they may feel ashamed
because of stigma.
Integrate the care of HIV-positive pregnant
women into the RCHC.
Option B+
Antenatal
prophylaxis
There are inconsistencies between the ARV
drugs prescribed in the RCHC and the ARV
drugs recorded in the labour ward books.
Probably mistakes when filling the books at the
labour ward.
CME. SOP.
Option B+.
Delivery There is not enough information to assume that
intrapartum prophylaxis is correctly
administered.
Doses and frequency of the ARV are not easy to
remember.
CME. SOP.
Poster with the intrapartum prophylaxis
regimen.
Identify a staff member responsible for checking
the availability of ARV drugs in the labour ward.
Option B+.
After delivery There are no data showing that postpartum
prophylaxis is being administered in the
hospital.
The staff do not appear to know clearly who is
supposed to administer it (labour ward or
obstetric ward).
Lack of availability of ARV drugs in labour ward /
obstetric ward.
Doses and frequency of the ARV are not easy to
remember.
Clearly assign responsibilities and duties
SOP
Identify a staff member responsible for checking
the availability of ARV drugs in the labour ward/
obstetric ward
Poster with the postpartum prophylaxis.
Counsel the mother about ARV prophylaxis.
Option B+.
Perinatal period Postnatal prophylaxis is not always correctly
administered after discharge.
The staff do not seem to know clearly who is
supposed to administer it (labour ward, obstetric
ward or neonatal unit)
Lack of availability of ARV syrups.
Doses and frequency are not easy to remember.
Because the sooner the dose is given the
greater the protective effect, the labour ward
should be the responsible.
Identify a staff member responsible for checking
the availability of ARV syrups in the labour ward.
Poster with the postnatal prophylaxis regimen.
Counsel the mother about ARV prophylaxis for
the baby.
SOP.
Option B+.
Exposed infants
follow-up
There is no standardised follow-up for the
exposed infants.
The Guidelines do not specify where the follow
up should be done, what frequency, etc.
Integrate the follow-up of HIV-exposed infants
into the existing under-five health services.
SOP.
Generate special files for the exposed infants.
Attach these files to the mothers’ CDCI files.
RCHC = Reproductive and Child Health Clinic; CDCI = Chronic Disease Clinic of Ifakara; HIV = Human Immunodeficiency Virus; CME = continuing medical education;
SOP = Standard Operating Procedure; ART = Antiretroviral Therapy; ARV = Antiretroviral; AZT = zidovudine; 3TC = lamivudine; NVP = nevirapine;
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other than the Chronic Disease Clinic of Ifakara, but we do
not consider this is a common or representative occurrence.
With Option B+, all HIV-positive pregnant women would
receive cART, avoiding suboptimal antiretroviral prophy-
laxis for women in need of cART for their own health.
For the antenatal prophylaxis prescribed, inconsistencies
between the antiretroviral regimens administered and the
records in the different services were observed. Concerning
intrapartum prophylaxis, the Tanzanian PMTCT guidelines
recommended using a combination of zidovudine, lam-
ivudine, and nevirapine. Our findings again show irregu-
larities in this crucial step. According to a study conduc-
ted in Malawi, skilled attendance at birth appeared to be
an important determinant of correct intrapartum prophy-
laxis [21]. In our setting, interviews with midwives re-
vealed a suboptimal knowledge of the recommended re-
gimens and doses. Postpartum and postnatal prophylaxes
are poorly implemented in sub-Saharan Africa [22–24].
Likewise, data on postpartum prophylaxis were nonexist-
ent in our hospital and only 1 out of 29 newborns received
correct postnatal prophylaxis. When antenatal and intra-
partum prophylaxis is correctly administered, between one-
third and one-half of all mother-to-child transmission of
HIV is estimated to occur during the postpartum period,
mostly through breastfeeding [25]. Thus, a good and up-
dated knowledge on postpartum and postnatal prophylaxes
among staff working on maternity wards would make pos-
sible to maximise the chance that mother-baby pairs get ap-
propriate and timely medications. However, frequent staff
turnover and attendance by junior clinicians present addi-
tional obstacles to the capacitation and continuing medical
education of attending staff.
With Option B+ the differences between antenatal, intra-
partum, and postpartum prophylaxis disappear. From the
moment the pregnant woman is diagnosed as HIV-positive,
she is prescribed lifelong cART, including pregnancy, de-
livery and breastfeeding periods. This is much simpler than
the current guidelines and the forthcoming Option A. By
adopting Option B+, the gaps arising from the complexity
of the drug combinations for different periods of prophy-
laxis would be avoided, as well as many infant infections
derived from the poor uptake of the more complex recom-
mendations. Concerns about drug compliance have been
raised because some women will be asymptomatic and feel
healthy. As seen in a Brazilian study, we expect pregnant
women to be highly motivated to protect their babies, es-
pecially if they are periodically counselled and a simple
regimen with not many pills per day is prescribed [26].
Extra counselling focused on minimising the possibility
of treatment interruption between pregnancies and its con-
sequences might be necessary for asymptomatic mothers
after the delivery and the breastfeeding period.
Similarly, postnatal prophylaxis would be simplified with
Option B+. With this option, all HIV-exposed infants re-
ceive antiretroviral prophylaxes for four to six weeks, re-
gardless of the feeding method. In contrast, with the current
recommendations and with the forthcoming coming Option
A, there are different regimens depending on the feeding
method, which again add complexity to their implementa-
tion in the field.
Follow-up of HIV-exposed infants is notoriously weak in
sub-Saharan Africa and it leads to under-diagnosis of HIV
[27], and our analysis confirms these findings in our set-
ting. According to data from the WHO, in 2010, in 65 re-
porting countries only 28% of the HIV-exposed infants had
an HIV test within the first two months of life [28]. Con-
curring with other studies from Kenya and Mozambique
[29, 30], a recent study from Ethiopia showed that slightly
more than 50% of HIV-exposed infants were followed-up
at six weeks and less than one-third had a documented
HIV test result. Remarkably, this low coverage of HIV test-
ing occurred in the frame of an immunisation coverage of
more than 80% among HIV-exposed infants [31], suggest-
ing specific problems related to HIV testing. Integration
of the follow-up of HIV-exposed infants into the existing
under-five child health clinics would maximise the oppor-
tunities for prompt diagnosis and timely treatment for HIV-
infected children. Unfortunately, the lack of a standard-
ised follow-up of HIV-exposed infants cannot directly be
bridged by implementing Option B+. However, by provid-
ing Option B+ it is probable that the follow-up of HIV-
exposed infants will improve, since more mothers will get
medical care. Moreover, with this option, fewer infants are
expected to be infected, so the number of undiagnosed in-
fants will decrease.
Based on our findings, several programmatic solutions can
be proposed to increase the uptake of current and forth-
coming PMTCT guidelines. The implementation of the
guidelines should be combined with a comprehensive
package including educational and logistic interventions to
be easily and affordably implemented in St Francis referral
hospital and other similar settings in sub-Saharan Africa.
Analogously, Youngleson et al. implemented a ‘change
package’ to improve the PMTCT programme in a sub-
district of Western Cape, South Africa, including maxim-
ising the use of existing resources, reducing duplication,
and developing patient-centred approaches. As a conse-
quence of this programme, significant improvements were
achieved, with a decrease in the perinatal transmission rate
from 7.6% to 5% [32]. The logistics of implementation
would be easier if Option B+ were adopted, mainly res-
ulting from a reduction in the training requirements. As a
consequence the likelihood of successful implementation
would be greatly increased.
Furthermore, apart from the simplification of the PMTCT
programme and its better implementation, lifelong cART
for HIV-infected pregnant women (Option B+) has addi-
tional benefits. By adopting this strategy, future pregnan-
cies will be protected from conception, and sexual trans-
mission of HIV to a seronegative partner will be signific-
antly reduced [33]. All women will require cART at some
point, with Option B+ they will merely start it earlier. In
this view, Option B+ can be placed in the frame of the idea
of ‘treatment as prevention’, which has attracted tremend-
ous interest and hope [33, 34].
Conclusions
In summary, we strongly believe that it is time to move for-
ward and argue in favour of the Option B+ strategy in Tan-
zania and other sub-Saharan Africa countries. Option B+
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is one of the most exciting developments in the prevention
of vertical transmission and paediatric HIV in the recent
years. Financial and operational challenges will have to be
overcome and the feasibility, the cost-benefit and the pub-
lic health impact will need to be assessed in those countries
implementing Option B+. Data from solid scientific studies
are still needed to support Option B+ definitively. Achiev-
ing the aim of the WHO for the ‘virtual elimination’ of pae-
diatric HIV, aiming to attain a mother-to-child transmission
risk of less than 5% for the year 2015, will be, even in the
best scenario, hard to do. Option B+ gives us for the first
time the opportunity to think that this goal is achievable at
a global scale. Strong political will and strong support from
governments and public health authorities will be needed to
achieve this milestone in the history of the HIV pandemic.
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Figures (large format)
Figure 1
Theoretical care pathway for prevention of mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) at St Francis Referral
Hospital (SFRH).
RCHC = Reproductive and Child Health Clinic; CDCI = Chronic Disease Clinic of Ifakara; ART = antiretroviral therapy; ARV = antiretroviral.
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Figure 2
Main gaps identified in the care pathway for prevention of mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) at St
Francis Referral Hospital (SFRH).
The gaps are coloured in brown. RCHC = Reproductive and Child Health Clinic; CDCI = Chronic Disease Clinic of Ifakara; ART = antiretroviral
therapy; ARV = antiretroviral.
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